Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
7 hedge funds and large institutions have $42K invested in Northwest Biotherapeutics, Inc. Common stock in 2019 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
40% more funds holding
Funds holding: 5 → 7 (+2)
8% more capital invested
Capital invested by funds: $39K → $42K (+$3K)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCG
Opus Capital Group
Cincinnati,
Ohio
|
+$3K |
| 2 |
WPP
Whalerock Point Partners
Providence,
Rhode Island
|
+$2.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$1.07K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WPP
1
Whalerock Point Partners
Providence,
Rhode Island
| $16K | +$2.4K | +9,000 | +18% |
|
|
SAM
2
Seelaus Asset Management
Chatham,
New Jersey
| $13K | – | – | – |
|
|
LDB
3
Lee, Danner & Bass
Nashville,
Tennessee
| $5K | – | – | – |
|
|
MPI
4
Mairs & Power Inc
St Paul,
Minnesota
| $3K | – | – | – |
|
|
OCG
5
Opus Capital Group
Cincinnati,
Ohio
| $3K | +$3K | +10,000 | New |
|
|
6
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $2K | -$1.07K | -3,200 | -35% |
|
NWBO Hedge Fund Activity: Q2 2019 in Review
7 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q2 2019, worth a combined $42K — up 7.7% from $39K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NWBO positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Opus Capital Group, opening a new position worth an estimated $3K. The largest seller was CAPTRUST Financial Advisors, cutting an estimated $1.07K.
- 7 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q2 2019, up from 5 in Q1 2019.
- Funds reported $42K of Northwest Biotherapeutics, Inc. Common stock stock for Q2 2019, up 7.7% quarter-over-quarter.
- 2 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q2 2019 and 0 closed out, a net change of +2 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q2 2019 was Opus Capital Group, an estimated $3K added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q2 2019 was CAPTRUST Financial Advisors, an estimated $1.07K sold.
Based on aggregated 13F filings for Q2 2019.